| 1/7 | US=16 / Estatística Kumar D, Verma M. Methods in cancer epigenetics and epidemiology. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 273-88. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1. CANCER. EPIDEMIOLOGIA; EPIGENETICA; ACETILACAO; BIOMARCADOR; CROMATINA; EPIGENETICA; HISTONA; HISTONA DESACETILASE (HDAC); HISTONA ACETILTRANSFERASE (HAT); METILACAO; METILTRANSFERASE; AVALIACAO DE RISCO; TRIAGEM |
| 2/7 | US=6 / Quimioterapia Airley R. Histone deacetylase: an epigenetic drug target. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 255-63. ISBN 978-0-470-09254-5. INIBIDORES DE HDAC; HISTONA DEACETILASE; DROGA EPIGENETICA; HDAC; EMBALAGEM DE DNA |
| 3/7 | US=67 / Biol/Mol Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2 |
| 4/7 | US=86 / Biol/Mol Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HAC inhibitor-induced apoptosis. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 261-98. (Advances in Experimental Medicina and Biology volume 615) ISBN 978-1-4020-6553-8. INIBIDORES DE HISTONA DESACETILASE; CANCER; APOPTOSE INDUZIDA POR INIBIDORES; INIBIDORES HDAC; HAT; SAHA; MS-275; TSA; TRAIL; CASPASE |
| 5/7 | US=90 / Biol/Mol Buck E, Eyzaguirre A, Iwata KK. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: utilizing combination of molecular targeted agents to sensitize tumor cells to EGFR inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 369-82. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EMT; TRANSICAO EPITELIAL MESENQUIMAL; ERLOTINIB; EGFR; IGF-1R; ER; HER3; MTOR; HDAC; SRC; COX-2 |
| 6/7 | US=2-A / Biol/Mol Marks PA. Molecular targets and therapeutics: histone deacetylase inhibitors: development as anticancer agents. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 1014-32. ISBN 978-3-527-31237-5. ALVOS MOLECULARES; TERAPEUTICA MOLECULAR; INIBIDORES DE HISTONA DEACETILASE; AGENTES ANTICANCER; ESTRUTURA DA CROMATINA; HDAC; ENSAIOS CLINICOS |
| 7/7 | US=517 / Tese/FAP Barros Filho MC. Expressão gênica global em carcinomas papilíferos de tireoide: busca de marcadores diagnósticos, prognósticos e alvos terapêuticos. [Global gene expression in papillary thyroid carcinoma: search for diagnostic, prognostic markers and therapeutic targets]. São Paulo, 2014. 145 p. Tese(Doutorado)-Fundação Antônio Prudente. EXPRESSAO GENICA; NEOPLASIAS DA GLANDULA TIREOIDE; PROGNOSTICO; DIAGNOSTICO; TERAPIA DE ALVO MOLECULAR |
